Last reviewed 2026-04-20 · How we verify

Contrave

At a glance

Approved indications

No approved indications tracked.

Boxed warnings

• WARNING: SUICIDAL THOUGHTS AND BEHAVIORS WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants for major depressive disorder and other psychiatric disorders. ( 5.1 ) Monitor for worsening and emergence of suicidal thoughts and behaviors. ( 5.1 ) CONTRAVE is not approved for use in pediatric patients. ( 5.1 ) SUICIDALITY AND ANTIDEPRESSA

Common side effects

• Nausea
• Headache
• Vomiting

Serious adverse events

• Myocardial infarction
• Tachycardia
• Cholecystitis
• Pneumonia
• Kidney infection
• Staphylococcal infection
• Presyncope
• Hematochezia

Key clinical trials

• Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1) (PHASE2, PHASE3)
• Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder (PHASE4)
• Pharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a) (PHASE2, PHASE3)
• A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America (PHASE4)
• Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders (PHASE2, PHASE3)
• Risk Factors Affect Weight Loss Outcomes After Treatment.
• Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE) (PHASE4)
• Sequential or CombinaTion Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial) (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.